Last reviewed · How we verify

USWM, LLC (dba US WorldMeds) — Portfolio Competitive Intelligence Brief

USWM, LLC (dba US WorldMeds) pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
lofexidine HCl lofexidine HCl marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Addiction Medicine / Substance Use Disorder
Open Label Lofexidine HCL Open Label Lofexidine HCL phase 3 Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Addiction Medicine / Substance Use Disorder

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American University of Beirut Medical Center · 1 shared drug class
  2. China International Neuroscience Institution · 1 shared drug class
  3. Derm Research, PLLC · 1 shared drug class
  4. Eye Therapies, LLC · 1 shared drug class
  5. Galderma R&D · 1 shared drug class
  6. Guangzhou Women and Children's Medical Center · 1 shared drug class
  7. Icahn School of Medicine at Mount Sinai · 1 shared drug class
  8. Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for USWM, LLC (dba US WorldMeds):

Cite this brief

Drug Landscape (2026). USWM, LLC (dba US WorldMeds) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/uswm-llc-dba-us-worldmeds. Accessed 2026-05-17.

Related